Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
John Radcliffe Hospital, Oxford, UK.
Scand J Gastroenterol. 2021 Sep;56(9):1049-1055. doi: 10.1080/00365521.2021.1947368. Epub 2021 Jul 14.
One-third of patients with acute severe ulcerative colitis (ASC) fail to respond to intravenous corticosteroids (IVCS) and require second-line therapy or colectomy. We aimed to explore the performance of the Pediatric Ulcerative Colitis Activity Index (PUCAI), for predicting response to IVCS in adults with ASC, and to base a two-step decision-making process for guiding the introduction of second-line therapy.
This was a retrospective multicenter cohort study of adult patients with ASC. PUCAI score, Oxford criteria, and Swedish index were determined at baseline, day three and five of hospitalization, and discharge when outcomes were ascertained.
153 patients were included (mean age 34.7 ± 14.6, median disease duration 7.8 years [IQR 0-17.4]), of whom 51 (33%) required second-line therapy, and 23 (15%) eventually underwent colectomy by discharge. At days three and five, the median PUCAI scores were higher in non-responders compared with responders (55 [45-69] 38 [25-55] at day 3, and 55 [36-65] 20 [5-30] at day 5; both < .001). The negative and positive predictive values (NPV and PPV) of IVCS failure were 76/63% for the Oxford criteria, 83/52% for the Swedish index as determined on day 3, and 73/100% for PUCAI ≥ 65 points on day five. The corresponding figures for PUCAI ≥ 45 at day 3 were 83/54%.
The PUCAI is a highly predictive tool for IVCS failure. PUCAI ≥ 45 on day 3 has an excellent NPV for IVCS failure indicating preparation for second-line therapy, and PUCAI ≥ 65 on day 5 has a high PPV to initiate the therapy.
三分之一的急性重度溃疡性结肠炎(ASC)患者对静脉注射皮质类固醇(IVCS)无反应,需要二线治疗或结肠切除术。我们旨在探讨儿科溃疡性结肠炎活动指数(PUCAI)在预测 ASC 成人对 IVCS 反应中的表现,并为指导二线治疗的引入制定两步决策过程。
这是一项回顾性多中心 ASC 成人队列研究。在住院第 3 天和第 5 天以及出院时确定 PUCAI 评分、牛津标准和瑞典指数。
共纳入 153 例患者(平均年龄 34.7±14.6 岁,中位疾病持续时间 7.8 年[IQR 0-17.4]),其中 51 例(33%)需要二线治疗,23 例(15%)最终在出院时行结肠切除术。在第 3 天和第 5 天,未 responders 的中位数 PUCAI 评分高于 responders(第 3 天 55[45-69] 38[25-55],第 5 天 55[36-65] 20[5-30];均 <0.001)。第 3 天牛津标准、瑞典指数和第 5 天 PUCAI≥65 点的 IVCS 失败的阴性预测值(NPV)和阳性预测值(PPV)分别为 76/63%、83/52%和 73/100%。第 3 天 PUCAI≥45 点的相应数值为 83/54%。
PUCAI 是预测 IVCS 失败的高度敏感工具。第 3 天的 PUCAI≥45 点对 IVCS 失败有极好的 NPV,提示准备二线治疗,第 5 天的 PUCAI≥65 点对启动治疗有很高的 PPV。